Could Summit Therapeutics Become the Next Merck? [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Many pharmaceutical and biotech companies have one or a few main areas of expertise in which they develop and market their most important medicines. For Merck (NYSE: MRK) , one of the most prominent companies in the business, that area is oncology. Merck is best known for its cancer drug Keytruda, which has been the best-selling medicine in the world since last year. It has several other cancer drugs in its portfolio although their sales pale compared to Keytruda's. However, one company wants to challenge Merck's crown jewel: Summit Therapeutics (NASDAQ: SMMT) . This California-based biotech is developing a cancer medicine that has produced excellent clinical trial results in one area where Keytruda is the leader. Summit Therapeutics still has no products on the market, but could it follow in the footsteps of its much larger peer? Summit Therapeutics' great move They say a company's management team is one of the most critical factors in its success, or lack thereof. We have at
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Stock Market News for Oct 4, 2024 [Yahoo! Finance]Yahoo! Finance
- Should Weakness in Merck & Co., Inc.'s (NYSE:MRK) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? [Yahoo! Finance]Yahoo! Finance
- U.S. In Vitro Fertilization Market Analysis Report 2024-2030: Societal Norms and Attitudes Shift, Driving IVF Demand [Yahoo! Finance]Yahoo! Finance
- ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors [Yahoo! Finance]Yahoo! Finance
- Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.MarketBeat
MRK
Earnings
- 7/30/24 - Beat
MRK
Sec Filings
- 10/1/24 - Form 4
- 10/1/24 - Form 4
- 10/1/24 - Form 4
- MRK's page on the SEC website